TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11136285

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid alone (10 mg.day/kg)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Combination therapy (chenodeoxycholic acid plus ursodeoxycholic acid, 5 mg.day/kg each)
Number of subjects: 154
Study: 9700583

Group type: EXPERIMENTAL
Intervention: Clodronate 1,600 mg/day for one year
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 66
Study: 7850850

Group type: EXPERIMENTAL
Intervention: 3 quick rinses with 10 ml of water (experiment A)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1 long-lasting rinse with 5 ml of water (experiment B)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: No water rinse after toothbrushing (experiment C)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ingestion of toothpaste slurry with 100 ml of de-ionized water (experiment D)
Number of subjects: 8
Study: 3139730

Group type: EXPERIMENTAL
Intervention: Astemizole, 10 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Terfenadine, 60 mg twice daily
Number of subjects: 60
Study: 28249384

Group type: EXPERIMENTAL
Intervention: Rebound exercise (30 minutes, three times per week for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (reading health magazines or watching television)
Number of subjects: 60
Study: 27236732

Group type: EXPERIMENTAL
Intervention: Curative treatment (surgery, radiosurgery, or embolization)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Embolization prior to surgery or radiosurgery
Number of subjects: 540

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 540
Study: 24736200

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D [25(OH)D] levels
Number of subjects: 530
Study: 23544333

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (1 mg x kg(‐1), 50 mg max) administered before surgery in group F (n = 11)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (group C, n = 13) with no flurbiprofen administration
Number of subjects: 24
Study: 20723545

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs) for patients with early-onset anemia (≤ 8 weeks of treatment)
Number of subjects: 3023

Group type: COMPARATOR
Intervention: No ESA use in patients with early-onset anemia
Number of subjects: 3023

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs) for patients with late-stage anemia
Number of subjects: 3023

Group type: EXPERIMENTAL
Intervention: Magnitude of Hb decrease (>3 g/dL)
Number of subjects: 3023

Group type: EXPERIMENTAL
Intervention: Magnitude of Hb decrease (≤3 g/dL)
Number of subjects: 3023
Study: 18221349

Group type: EXPERIMENTAL
Intervention: Child sexual abuse
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Hopelessness
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Juvenile onset major depression
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Chronic major depressive disorder
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: High adversity
Number of subjects: 158
Study: 16190095

Group type: EXPERIMENTAL
Intervention: Diazepam (DZ)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12720050

Group type: EXPERIMENTAL
Intervention: Menaquinone 4 (MK(4)) at a dose of 45 mg/day for 2 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Calcium alone for 2 weeks (Control)
Number of subjects: 20
Study: 10321403

Group type: EXPERIMENTAL
Intervention: READER method
Number of subjects: 92

Group type: COMPARATOR
Intervention: Free appraisal
Number of subjects: 92
Study: 8912486

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Sumatriptan (100 mg)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Rizatriptan (10 mg)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Rizatriptan (20 mg)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Rizatriptan (40 mg)
Number of subjects: 449
Study: 1365485

Group type: EXPERIMENTAL
Intervention: droxicam (20mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: indomethacin (100mg/day)
Number of subjects: 20
Study: 6351216

Group type: EXPERIMENTAL
Intervention: Aspirin (1 g)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Aspirin + Dipyridamole (ASA + D)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Aspirin + Dipyridamole (AD)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) and Aspirin + Dipyridamole (AD)
Number of subjects: 604
Study: 29926432

Group type: EXPERIMENTAL
Intervention: Watching the film
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 81
Study: 30091979

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 27100375

Group type: EXPERIMENTAL
Intervention: Composite intervention including a personalized weight graph, education on recommended weight gain, prescription of exercise, and monitoring of weight until 1 year after delivery
Number of subjects: 445

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Composite intervention
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Gestational weight gain above Institute of Medicine recommendations
Number of subjects: 445
Study: 25139698

Group type: EXPERIMENTAL
Intervention: Trunk-to-head bathing
Number of subjects: 62

Group type: COMPARATOR
Intervention: Head-to-trunk bathing (Control)
Number of subjects: 62
Study: 22275142

Group type: EXPERIMENTAL
Intervention: Esreboxetine 4 mg/day
Number of subjects: 1122

Group type: EXPERIMENTAL
Intervention: Esreboxetine 8 mg/day
Number of subjects: 1122

Group type: EXPERIMENTAL
Intervention: Esreboxetine 10 mg/day
Number of subjects: 1122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1122
Study: 20619634

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy with sequential chemotherapy
Number of subjects: 540

Group type: COMPARATOR
Intervention: Adjuvant radiotherapy alone
Number of subjects: 540
Study: 18156031

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus interferon alfa-2a (10 mg/kg every 2 weeks; 9 MIU subcutaneously three times weekly)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Placebo plus interferon alfa-2a (9 MIU subcutaneously three times weekly)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus interferon alfa-2a
Number of subjects: 649

Group type: COMPARATOR
Intervention: Placebo plus interferon alfa-2a
Number of subjects: 649
Study: 15153904

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1% applied twice daily
Number of subjects: 1

Group type: COMPARATOR
Intervention: Inactive vehicle applied twice daily
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Patch testing with tacrolimus 2.5% in ethanol
Number of subjects: 1
Study: 11240334

Group type: EXPERIMENTAL
Intervention: Jejunal feeding (JF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 9519948

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg twice daily for 6 months
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 281
Study: 7595697

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HD-CNV) with cyclophosphamide 2.4 g/m2, mitoxantrone 35 to 45 mg/m2, and etoposide (VP16) 2.5 g/m2
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy (CNV) with cyclophosphamide 600 mg/m2, mitoxantrone 12 mg/m2, and vincristine 1.4 mg/m2
Number of subjects: 90
Study: 2625542

Group type: EXPERIMENTAL
Intervention: 70 dB white noise with varying illumination levels (50, 150, 300 lx)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 dB white noise with varying illumination levels (50, 150, 300 lx)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 70 dB white noise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Illumination levels (50, 150, 300 lx)
Number of subjects: 12
Study: 1108600

Group type: EXPERIMENTAL
Intervention: Equine anti-human-lymphocyte globulin (ALG)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 31922899

Group type: EXPERIMENTAL
Intervention: Active continuous positive airway pressure (CPAP) for 3 months
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sham continuous positive airway pressure (CPAP) for 3 months
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 53
Study: 29762517

Group type: EXPERIMENTAL
Intervention: Legislation to restrict HFSS TV advertising until 9:30 pm
Number of subjects: 0
Study: 27392007

Group type: EXPERIMENTAL
Intervention: Family-based intervention designed to enhance resilience and communication in families affected by caregiver HIV.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 0
Study: 24232192

Group type: EXPERIMENTAL
Intervention: Supervised physical activity plus behavioral counseling (SPA + BC group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Supervised physical activity plus standard exercise counseling (SPA + EC group)
Number of subjects: 32
Study: 23593156

Group type: EXPERIMENTAL
Intervention: New occlusal adjustment therapy
Number of subjects: 21
Study: 19229275

Group type: EXPERIMENTAL
Intervention: Standard of care plus nepafenac for 1 month
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard of care (topical antibiotic for 10 days and topical corticosteroid for 1 month)
Number of subjects: 79
Study: 18709032

Group type: EXPERIMENTAL
Intervention: 0.5 mg epidural butorphanol with bupivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.75 mg epidural butorphanol with bupivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.125% bupivacaine alone
Number of subjects: 120
Study: 15341548

Group type: EXPERIMENTAL
Intervention: Group exercise and coping classes (6 months, 3 meetings weekly, 45 minutes each for exercise and 2 meetings weekly, 45 minutes each for coping)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Health education control intervention (6 months, 1 meeting weekly, 45 minutes)
Number of subjects: 185
Study: 11080603

Group type: EXPERIMENTAL
Intervention: Psycho-educational program (2-day duration)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 30
Study: 9828976

Group type: EXPERIMENTAL
Intervention: Intervention: HIV preventive programme
Number of subjects: 1004
Study: 7569150

Group type: EXPERIMENTAL
Intervention: Continuous combined therapy (CCT) with 2 mg estradiol valerate and 2.5 mg medroxyprogesterone acetate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 2804252

Group type: EXPERIMENTAL
Intervention: Slow release theophylline tablets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Slow release theophylline granules
Number of subjects: 24

Group type: COMPARATOR
Intervention: Institutionalized group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study: 1211536

Group type: EXPERIMENTAL
Intervention: Heineke-Mikulicz pyloroplasty
Number of subjects: 200

Group type: COMPARATOR
Intervention: Finney pyloroplasty
Number of subjects: 200
Study: 31900673

Group type: EXPERIMENTAL
Intervention: IPS InLine veneers with thickness L1 (0.2-0.5 mm)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IPS InLine veneers with thickness L2 (0.5-1.2 mm)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups (including various preparation designs)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Thin veneers and preparations with medium to high dentin portions
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Preexisting resin composite restorations
Number of subjects: 80
Study: 31018565

Group type: EXPERIMENTAL
Intervention: EATS (Eating Advice to Students) web-based nutrition intervention
Number of subjects: 124

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 124
Study: 28649001

Group type: COMPARATOR
Intervention: Vincristine and Carboplatin (VC)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Vincristine, Carboplatin, and Etoposide (VCE)
Number of subjects: 497
Study: 26198394

Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes (VLNC) at 0.5 mg/cigarette for 7 months followed by 12 months with no intervention
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual brand of cigarettes
Number of subjects: 135
Study: 23538479

Group type: EXPERIMENTAL
Intervention: Antiplatelet or anticoagulant therapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: No antiplatelet or anticoagulant therapy
Number of subjects: 104
Study: 20226548

Group type: EXPERIMENTAL
Intervention: Argatroban (ARG250: 250 μg/kg bolus, 15 μg/kg/min infusion)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Argatroban (ARG300: 300 μg/kg bolus, 20 μg/kg/min infusion)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Argatroban (ARG350: 350 μg/kg bolus, 25 μg/kg/min infusion)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH: 70-100 IU/kg bolus)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Argatroban (all doses)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Argatroban (ARG250: 2.8%, ARG300: 0.0%, ARG350: 3.2%)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 138
Study: 19692798

Group type: EXPERIMENTAL
Intervention: GW406381 70 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: GW406381 50 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: GW406381 25 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: GW406381 10 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 16721551

Group type: EXPERIMENTAL
Intervention: Ceram.X/K‐0127
Number of subjects: 43

Group type: COMPARATOR
Intervention: Tetric Ceram/Syntac Classic
Number of subjects: 43
Study: 15249520

Group type: EXPERIMENTAL
Intervention: Risk communication training
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: SDM skill development
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Risk communication aids followed by SDM skill development
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Risk communication tools
Number of subjects: 747
Study: 11751349

Group type: EXPERIMENTAL
Intervention: Remote, retroactive intercessory prayer
Number of subjects: 3393

Group type: COMPARATOR
Intervention: Control group (no prayer)
Number of subjects: 3393
Study: 9425968

Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine (100 microg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Droperidol (0.5 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol (2-4 mg/kg/h)
Number of subjects: 100
Study: 8248762

Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds (PPTs) measured with a handheld electronic pressure algometer (Somedic®)
Number of subjects: 12
Study: 3307727

Group type: EXPERIMENTAL
Intervention: Buprenorphine by intermittent intravenous injection
Number of subjects: 13

Group type: COMPARATOR
Intervention: Morphine by continuous intravenous infusion
Number of subjects: 13
Study: 30593142

Group type: EXPERIMENTAL
Intervention: NMES therapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sham NMES
Number of subjects: 82
Study: 27260592

Group type: EXPERIMENTAL
Intervention: Articulation therapy (40 intensive sessions over 10 weeks)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Articulation therapy
Number of subjects: 5
Study: 25002136

Group type: EXPERIMENTAL
Intervention: Phosphorus (500 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 22474864

Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21087898

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg daily for 5 years)
Number of subjects: 6241
Study: 18281670

Group type: EXPERIMENTAL
Intervention: vitespen (autologous, tumor-derived heat shock protein gp96 peptide complexes)
Number of subjects: 322

Group type: COMPARATOR
Intervention: physician's choice (PC) of treatment (dacarbazine, temozolomide, interleukin-2, or complete tumor resection)
Number of subjects: 322
Study: 15472642

Group type: EXPERIMENTAL
Intervention: Usual strategy supplemented by resting myocardial perfusion imaging (MPI) using SPECT technetium 99m sestamibi (n = 153)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Usual strategy (n = 188)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Usual strategy supplemented by resting MPI (n = 153)
Number of subjects: 341
Study: 11337242

Group type: EXPERIMENTAL
Intervention: Lateral head (LH) of the hamstring muscles during maximum isometric contraction at 45 degrees of knee flexion
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lateral head (LH) of the hamstring muscles during submaximal isometric contractions
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Medial head (MH) of the hamstring muscles during submaximal isometric contractions
Number of subjects: 42
Study: 9215817

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 40 mg four times daily
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) 250 mg four times daily with hydrocortisone (HC) 40 mg daily
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Combination of MA plus AG at the same dosages
Number of subjects: 288
Study: 7955237

Group type: EXPERIMENTAL
Intervention: Medical treatment alone
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 468
Study: 2447997

Group type: EXPERIMENTAL
Intervention: goserelin 3.6 mg depot (Zoladex)
Number of subjects: 139

Group type: COMPARATOR
Intervention: stilboestrol 3 mg/day
Number of subjects: 139
Study: 29965952

Group type: EXPERIMENTAL
Intervention: Transplant education (less than 1 hour)
Number of subjects: 1294

Group type: COMPARATOR
Intervention: Transplant education (1 hour or longer)
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: Talking to doctors/medical staff
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: Reading brochures
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: Browsing the internet
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: Watching videos
Number of subjects: 1294
Study: 30145929

Group type: EXPERIMENTAL
Intervention: 80 mg of tafamidis
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: 20 mg of tafamidis
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Tafamidis (both dosages)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 27318021

Group type: EXPERIMENTAL
Intervention: Vardenafil administered via inhalation using an ultrasonic nebulizer
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vardenafil 10-mg oral tablet
Number of subjects: 12
Study: 24504819

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 22891807

Group type: EXPERIMENTAL
Intervention: Interactive version of an injection risk intervention and sexual risk intervention (single 60-minute session)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Didactic version of an injection risk intervention and sexual risk intervention (single 60-minute session)
Number of subjects: 584
Study: 20675363

Group type: EXPERIMENTAL
Intervention: Smoking characters
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-smoking characters
Number of subjects: 60
Study: 17617790

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Continuous infusion (CI)
Number of subjects: 19
Study: 15894537

Group type: EXPERIMENTAL
Intervention: Strength Training (10-week single-leg knee-extension program)
Number of subjects: 67
Study: 11240954

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus (FK506)
Number of subjects: 10
Study: 9248782

Group type: EXPERIMENTAL
Intervention: Amoxycillin (1 g, Clamoxyl dispersible tablet)
Number of subjects: 20
Study: 8497019

Group type: EXPERIMENTAL
Intervention: Light group (lifted less weight than they believed)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Heavy group (lifted more weight than they believed)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no manipulation)
Number of subjects: 24
Study: 3826206

Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptives
Number of subjects: 12
Study: 31409749

Group type: EXPERIMENTAL
Intervention: Ropinirole eye drops (3.75 mg/m2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ropinirole eye drops
Number of subjects: 100
Study: 30102656

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Nevirapine (NVP)
Number of subjects: 449
Study: 28678855

Group type: EXPERIMENTAL
Intervention: PowerPoint presentations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prezi presentations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral presentations
Number of subjects: 0
Study: 26152472

Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation Plus (PAV+)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 160

Group type: COMPARATOR
Intervention: T-Tube Ventilation
Number of subjects: 160
Study: 23715579

Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 183

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 183
Study: 21232119

Group type: EXPERIMENTAL
Intervention: Oral vitamin B12 (1000 μg daily, N = 26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (N = 24)
Number of subjects: 50
Study: 18633597

Group type: EXPERIMENTAL
Intervention: Minimal invasive surgery (MIS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Computer assisted surgery with minimal invasive approach (CAS-MIS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups (MIS, CAS-MIS, Conventional)
Number of subjects: 90